Trinity College Dublin

Skip to main content.

Top Level TCD Links

Stephen Finn
Associate Professor Consultant, Histopathology

Biography

Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is a Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is co-director of the Cancer Molecular Diagnostic Laboratory, the only fully accredited molecular diagnostic laboratory in Ireland. His clinical practice is limited to Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health, the Dana Farber Cancer Institute and the University of Orebro in Sweden. Dr. Finn is a member of the Irish Prostate Cancer Research Consortium (PCRC) and the Transdisciplinary Prostate Cancer Partnership ToPCaP. Dr. Finn, a current recipient of the Prostate Cancer Foundation Young investigator Award, and is committed to forging a career as an independent researcher focused on prostate cancer and bringing his skills as a clinician, pathologist and scientist to bear on critical questions of clinical relevance to men who suffer from aggressive prostate cancer.

Publications and Further Research Outputs

Peer-Reviewed Publications

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International Journal of Oncology, 48, (3), 2016, p1290-1296 Journal Article, 2016 DOI

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., 2016 Journal Article, 2016

Staunton, L., Tonry, C., Lis, R., Finn, S., O'Leary, J., Loda, M., Bowden, M., Pennington, S.R., Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS-A technical report, EuPA Open Proteomics, 10, 2016, p19-23 Journal Article, 2016

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA, Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression., 2016 Journal Article, 2016

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International journal of oncology, 48, (3), 2016, p1290-6 Journal Article, 2016 DOI

Leon, G., MacDonagh, L., Finn, S.P., Cuffe, S., Barr, M.P., Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways, Pharmacology and Therapeutics, 2016 Journal Article, 2016

Stahel, R., Bogaerts, J., Ciardiello, F., de Ruysscher, D., Dubsky, P., Ducreux, M., Finn, S., Laurent-Puig, P., Peters, S., Piccart, M., Smit, E., Sotiriou, C., Tejpar, S., Van Cutsem, E., Tabernero, J., Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development, Cancer Treatment Reviews, 41, (2), 2015, p129-135 Journal Article, 2015

MacDonagh,Lauren , Gray,Steven George, Finn,Stephen P. , Cuffe,Sinead D. , O'Byrne,Kenneth John, Barr,Martin P. , The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160-169 Journal Article, 2015 DOI

Quinn, L., Finn, S.P., Cuffe, S., Gray, S.G., Non-coding RNA repertoires in malignant pleural mesothelioma, Lung Cancer, 90, (3), 2015, p417-426 Journal Article, 2015

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients., 2015 Journal Article, 2015

Rider, J.R., Fiorentino, M., Kelly, R., Gerke, T., Jordahl, K., Sinnott, J.A., Giovannucci, E.L., Loda, M., Mucci, L.A., Finn, S., Tumor expression of adiponectin receptor 2 and lethal prostate cancer, Carcinogenesis, 36, (6), 2015, p639-647 Journal Article, 2015

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL, A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer., Journal of the National Cancer Institute, 108, (2), 2015 Journal Article, 2015 DOI

Anne-Marie Byrne , Spiros Bekiaris, Gina Duggan, David Prichard, Murat Kirca, Stephen Finn, John V Reynolds, Dermot Kelleher and Aideen Long, Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion, British Journal of Cancer, 113, 2015, p1332-1342 Journal Article, 2015 DOI TARA - Full Text

Lochrin, S.E., Figg, W.D., Finn, S.P., Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance, Cancer Biology and Therapy, 16, (2), 2015, p201-203 Journal Article, 2015

Martin, N.E., Gerke, T., Sinnott, J.A., Stack, E.C., Andren, O., Andersson, S.-O., Johansson, J.-E., Fiorentino, M., Finn, S., Fedele, G., Stampfer, M., Kantoff, P.W., Mucci, L.A., Loda, M., Measuring PI3K activation: Clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer, Molecular Cancer Research, 13, (10), 2015, p1431-1440 Journal Article, 2015

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K, Strategic targeting of the PI3K-NF"B axis in cisplatin-resistant NSCLC., Cancer biology & therapy, 15, (10), 2014, p1367-77 Journal Article, 2014 DOI

Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH, European Society of Pathology Task Force on Quality Assurance in Molecular Pathology, Royal College of Pathologists, Guidance for laboratories performing molecular pathology for cancer patients., 2014 Journal Article, 2014

Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C.N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S.P., Fosså, S., Gillessen, S., Kellokumpu-Lehtinen, P.-L., Lecouvet, F.E., Oudard, S., De Reijke, T.M., Robson, C.N., De Santis, M., Seruga, B., De Wit, R., Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel, European Journal of Cancer, 50, (9), 2014, p1617-1627 Journal Article, 2014

O'Brien CP, Taylor SE, O'Leary JJ, Finn SP, Molecular testing in oncology: Problems, pitfalls and progress., Lung cancer (Amsterdam, Netherlands), 2014 Journal Article, 2014 TARA - Full Text DOI

O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP, Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns., Molecular diagnosis & therapy, 18, (1), 2014, p1-4 Journal Article, 2014 DOI

O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP., The role of DNA repair pathways in cisplatin resistant lung cancer, Cancer Treatment Reviews, 40, (10), 2014, p1161 - 1170 Review Article, 2014 URL

Nur MM, Finn S, Reynolds JV, Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells., Expert review of anticancer therapy, 14, (3), 2014, p267-9 Journal Article, 2014 DOI

Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA, SPINK1 protein expression and prostate cancer progression., Clinical cancer research : an official journal of the American Association for Cancer Research, 20, (18), 2014, p4904-11 Journal Article, 2014 TARA - Full Text DOI

Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N, Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience., Irish medical journal, 107, (7), 2014, p201-4 Journal Article, 2014

Hayes BD, Finn SP, Kidney volume correlates with tumor diameter in renal cell carcinoma and is associated with histological poor prognostic features., International journal of surgical pathology, 22, (1), 2014, p39-46 Journal Article, 2014

Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9, (11), 2014, p1675-84 Journal Article, 2014 DOI

d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ, The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer., PloS one, 9, (6), 2014, pe100816 Journal Article, 2014 DOI TARA - Full Text

Seiwert, T.Y., Wang, X., Heitmann, J., Villegas-Bergazzi, V., Sprott, K., Finn, S., O'Regan, E., Farrow, A.D., Weichselbaum, R.R., Lingen, M.W., Cohen, E.E.W., Stenson, K., Weaver, D.T., Vokes, E.E., DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer, PLoS ONE, 9, (7), 2014 Journal Article, 2014

O'Brien CP, Finn SP, Application of statistical process control to qualitative molecular diagnostic assays., Frontiers in molecular biosciences, 1, 2014, p18 Journal Article, 2014 DOI TARA - Full Text

Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA, Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG., Journal of the National Cancer Institute, 105, (24), 2013, p1881-90 Journal Article, 2013

Guevara G, O'Connor E, McCormack O, Harmon M, Finn S, Muldoon C, Ravi N, Reynolds JV, Diffuse oesophageal leiomyomatosis., ANZ journal of surgery, 2013 Journal Article, 2013 TARA - Full Text DOI

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA, Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (12), 2013, p2354-63 Journal Article, 2013

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E, Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (11), 2013, p1984-93 Journal Article, 2013

Mee, B., Gaffney, E., Glynn, S.A., Donatello, S., Carroll, P., Connolly, E., Mc Garrigle, S., Boyle, T., Flannery, D., Sullivan, F.J., McCormick, P., Griffin, M., Muldoon, C., Fay, J., O'Grady, T., Kay, E., Eustace, J., Burke, L., Sheikh, A.A., Finn, S., Flavin, R., Giles, F.J., Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), Standardized documentation, sample and data release, and international perspective, Biopreservation and Biobanking, 11, (1), 2013, p3-11 Journal Article, 2013

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 Journal Article, 2013 TARA - Full Text DOI

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M, Gleason grade progression is uncommon., Cancer research, 73, (16), 2013, p5163-8 Journal Article, 2013

SL Doyle, C Donohoe, S Finn, J Howard, FE Lithander, JV Reynolds, G Pidgeon, J Lysaght , IGF-1 and its Receptor in Esophageal Cancer: Association with Adenocarcinoma and Visceral Obesity, American Journal of Gastroenterology, 107, 2012, p196 - 204 Journal Article, 2012 DOI URL

Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O, RET protein expression in papillary renal cell carcinoma., Urologic oncology, 30, (6), 2012, p900-5 Journal Article, 2012

Fiore C, Bailey D, Conlon N, Wu X, Martin N, Fiorentino M, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R, Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry., Journal of clinical pathology, 65, (6), 2012, p496-502 Journal Article, 2012

Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J, IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity., The American journal of gastroenterology, 107, (2), 2012, p196-204 Journal Article, 2012

Dhillon, P.K., Penney, K.L., Schumacher, F., Rider, J.R., Sesso, H.D., Pollak, M., Fiorentino, M., Finn, S., Loda, M., Rifai, N., Mucci, L.A., Giovannucci, E., Stampfer, M.J., Jing, M., Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer, Cancer Epidemiology Biomarkers and Prevention, 20, (12), 2011, p2618-2627 Journal Article, 2011

Karl Egan., Darragh Crowley., Paul Smyth, Sharon O'Toole, Cathy Spillane, Cara Martin, Michael Gallagher, Aoife Canney, Lucy Norris, Niamh Conlon, Lynda McEvoy2, Brendan Ffrench2, Britta Stordal, Helen Keegan, Stephen Finn, Victoria McEneaney, Alex Laios, Jens Ducre, Eimear Dunne, Leila Smith, Michael Berndt, Orla Sheils, Dermot Kenny, John O'Leary, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011 Journal Article, 2011 TARA - Full Text

Penney, K.L., Sinnott, J.A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., Stark, J.R., Fiorentino, M., Perner, S., Finn, S., Calza, S., Flavin, R., Freedman, M.L., Setlur, S., Sesso, H.D., Andersson, S.-O., Martin, N., Kantoff, P.W., Johansson, J.-E., Adami, H.-O., Rubin, M.A., Loda, M., Golub, T.R., Andrén, O., Stampfer, M.J., Mucci, L.A., mRNA expression signature of gleason grade predicts lethal prostate cancer, Journal of Clinical Oncology, 29, (17), 2011, p2391-2396 Journal Article, 2011

Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L, Immunohistochemical expression of BRCA1 and lethal prostate cancer., Cancer research, 70, (8), 2010, p3136-9 Journal Article, 2010 DOI

Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA, Genetic variation in RNASEL associated with prostate cancer risk and progression., Carcinogenesis, 31, (9), 2010, p1597-603 Journal Article, 2010 DOI

Fiorentino, M., Judson, G., Penney, K., Flavin, R., Stark, J., Fiore, C., Fall, K., Martin, N., Ma, J., Sinnott, J., Giovannucci, E., Stampfer, M., Sesso, H.D., Kantoff, P.W., Finn, S., Loda, M., Mucci, L., Immunohistochemical expression of BRCA1 and lethal prostate cancer (Cancer Research (2010) 70, (3136-3139) DOI:10.1158/0008-5472.CAN-09-4100), Cancer Research, 70, (11), 2010 Journal Article, 2010

Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S, B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression., Proceedings of the National Academy of Sciences of the United States of America, 107, (23), 2010, p10649-54 Journal Article, 2010 DOI TARA - Full Text

Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M, Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, (25), 2010, p3958-64 Journal Article, 2010 TARA - Full Text DOI

Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy., Nature biotechnology, 27, (1), 2009, p77-83 Journal Article, 2009 DOI

Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M, Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer., Journal of the National Cancer Institute, 101, (7), 2009, p519-32 Journal Article, 2009 DOI

Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A, Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer., The Journal of clinical investigation, 119, (5), 2009, p1093-108 Journal Article, 2009 DOI TARA - Full Text

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ, miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 19, (4), 2009, p641-7 Journal Article, 2009 DOI

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA, Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27, (21), 2009, p3459-64 Journal Article, 2009 TARA - Full Text DOI

Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M, FOXA1 is a potential oncogene in anaplastic thyroid carcinoma., Clinical cancer research : an official journal of the American Association for Cancer Research, 15, (11), 2009, p3680-9 Journal Article, 2009 DOI

Flavin, R., Smyth, P., Barrett, C., Russell, S., Wen, H., Wei, J., Laios, A., O'Toole, S., Ring, M., Denning, K., Li, J., Aherne, S., Sammarae, D., Aziz, N.A., Alhadi, A., Finn, S.P., Loda, M., Sheppard, B., Sheils, O., O'Leary, J.J., MiR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma, International Journal of Gynecological Cancer, 19, (4), 2009, p641-647 Journal Article, 2009

Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, Aherne ST, Sammarae DA, Aziz NA, Alhadi A, Sheppard BL, Lao K, Sheils OM, O'Leary JJ, Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 22, (2), 2009, p197-205 Journal Article, 2009 DOI

Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S, Systems-level modeling of cancer-fibroblast interaction., PloS one, 4, (9), 2009, pe6888 Journal Article, 2009 DOI

Flavin R, Jackl G, Finn S, Smyth P, Ring M, O'Regan E, Cahill S, Unger K, Denning K, Jinghuan Li Aherne S, Tallini G, Gaffney E, O'Leary JJ, Zitzelsberger H, Sheils O, RET/PTC rearrangement occurring in primary peritoneal carcinoma., International journal of surgical pathology, 17, (3), 2009, p187-97 Journal Article, 2009 DOI

Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J, Potential role of miR-9 and miR-223 in recurrent ovarian cancer., Molecular cancer, 7, 2008, p35 Journal Article, 2008 DOI

Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ, Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 21, (6), 2008, p676-84 Journal Article, 2008 DOI

Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC, CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity., Nature, 455, (7212), 2008, p547-51 Journal Article, 2008 DOI

O'Regan, E.M., Toner, M.E., Finn, S.P., Fan, C.Y., Ring, M., Hagmar, B., Timon, C., Smyth, P., Cahill, S., Flavin, R., Sheils, O.M., O'Leary, J.J., p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas, Human Pathology, 39, (3), 2008, p452-458 Journal Article, 2008

Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M, Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer., Laboratory investigation; a journal of technical methods and pathology, 88, (12), 2008, p1340-8 Journal Article, 2008 DOI

O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon C, Smyth P, Cahill S, Flavin R, Sheils OM, O'Leary JJ, p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas., Human pathology, 39, (3), 2008, p452-8 Journal Article, 2008 DOI

Nieto M, Finn S, Loda M, Hahn WC, Prostate cancer: Re-focusing on androgen receptor signaling., The international journal of biochemistry & cell biology, 39, (9), 2007, p1562-8 Journal Article, 2007 DOI

Finn S, Smyth P, O'Regan E, Cahill S, Toner M, Timon C, Flavin R, O'Leary J, Sheils O, Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines., Archives of pathology & laboratory medicine, 131, (1), 2007, p65-73 Journal Article, 2007 DOI

Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossage K, Gossard K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M, Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution., The Journal of molecular diagnostics : JMD, 9, (1), 2007, p20-9 Journal Article, 2007 DOI

Flavin R, Smyth P, Crotty P, Finn S, Cahill S, Denning K, Jinghuan Li O'Regan E, O'Leary J, Sheils O, BRAF T1799A mutation occurring in a case of malignant struma ovarii., International journal of surgical pathology, 15, (2), 2007, p116-20 Journal Article, 2007 DOI

O'Brien TP, Walsh MT, Kavanagh EG, Finn SP, Grace PA, McGloughlin TM, Surgical feasibility study of a novel polytetrafluoroethylene graft design for the treatment of peripheral arterial disease., Annals of vascular surgery, 21, (5), 2007, p611-7 Journal Article, 2007 DOI

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL, Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN., Cancer cell, 11, (6), 2007, p555-69 Journal Article, 2007 DOI

Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M, Toner M, Timon C, O'Leary JJ, Sheils OM, Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy., Virchows Archiv : an international journal of pathology, 450, (3), 2007, p249-60 Journal Article, 2007 DOI

Denning KM, Smyth PC, Cahill SF, Finn SP, Conlon E, Li J, Flavin RJ, Aherne ST, Guenther SM, Ferlinz A, O'Leary JJ, Sheils OM, A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 20, (10), 2007, p1095-102 Journal Article, 2007 DOI

Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ, Sheils O, Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model., Molecular cancer, 5, 2006, p70 Journal Article, 2006 DOI

Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M, The isopeptidase USP2a protects human prostate cancer from apoptosis., Cancer research, 66, (17), 2006, p8625-32 Journal Article, 2006 DOI

O'Regan EM, Toner ME, Smyth PC, Finn SP, Timon C, Cahill S, Flavin R, O'Leary JJ, Sheils O, Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients., Head & neck, 28, (4), 2006, p330-8 Journal Article, 2006 DOI

Guarner J, Bartlett J, Reagan S, Fischer M, Finn S, O'Briain DS, Black M, Hood J, Zaki SR, Immunohistochemical evidence of Clostridium sp, Staphylococcus aureus, and group A Streptococcus in severe soft tissue infections related to injection drug use., Human pathology, 37, (11), 2006, p1482-8 Journal Article, 2006 DOI

Smyth, P., Finn, S., Cahill, S., O'Regan, E., Flavin, R., O'Leary, J.J., Sheils, O., Ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic irish cohort of papillary thyroid carcinoma, International Journal of Surgical Pathology, 13, (1), 2005, p1-8 Journal Article, 2005

Flavin R, Finn S, McErlean A, Smyth P, Meaney J, O'Connell F, Kellett J, McGovern E, Gaffney E, Cannonball metastases with favourable prognosis., Irish journal of medical science, 174, (1), 2005, p61-4 Journal Article, 2005

Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ, Sheils O, ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma., International journal of surgical pathology, 13, (1), 2005, p1-8 Journal Article, 2005

Finn SP, Smyth P, O'regan E, Cahill S, Flavin R, O'leary J, Sheils O, Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes., Virchows Archiv : an international journal of pathology, 445, (4), 2004, p396-404 Journal Article, 2004 DOI

Smyth P, Finn S, O'Leary J, Sheils O, Real-time analysis of beta- and gamma-catenin mRNA expression in ret/PTC-1 activated and nonactivated thyroid tissues., Diagnostic molecular pathology : the American journal of surgical pathology, part B, 12, (1), 2003, p44-9 Journal Article, 2003

Murphy SM, Browne RF, Finn S, Myers E, Crotty P, Grainger R, Non-metastatic primitive peripheral neuroectodermal tumour of the kidney (extraskeletal Ewing's sarcoma) with vena caval tumour thrombus., BJU international, 92 Suppl 3, 2003, pe44 Journal Article, 2003

Sheils, O.M., Finn, S., O'Leary, J.J., Quality-control issues for PCR-based assays in the molecular laboratory , 9, (3), 2003, p165-172 Journal Article, 2003 DOI

Sheils, O., Finn, S., O'Leary, J., Nucleic acid microarrays: An overview, 9, (3), 2003, pPages 155-158 Journal Article, 2003 DOI

Finn, S.P., Smyth, P., O'Leary, J., Sweeney, E.C., Sheils, O., Comment: Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma, Journal of Clinical Endocrinology and Metabolism, 88, (2), 2003, p938-941 Journal Article, 2003

Finn SP, Smyth P, O'Leary J, Sweeney EC, Sheils O, Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma., The Journal of clinical endocrinology and metabolism, 88, (2), 2003, p938-41 Journal Article, 2003 DOI

Finn SP, Leen E, English L, O'Briain DS, Autopsy findings in an outbreak of severe systemic illness in heroin users following injection site inflammation: an effect of Clostridium novyi exotoxin?, Archives of pathology & laboratory medicine, 127, (11), 2003, p1465-70 Journal Article, 2003 DOI

SMYTH, P, SHEILS, O, FINN, S, MARTIN, C, OLEARY, J, SWEENEY, EC, REAL-TIME QUANTITATIVE ANALYSIS OF E-CADHERIN EXPRESSION IN RET/PTC-1-ACTIVATED THYROID NEOPLASMS, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 9, 2002, p265 - 272 Journal Article, 2002

SHEILS, OM, IN-VITRO AND IN-VIVO EVIDENCE OF AN ASSOCIATION BETWEEN RET/PTC EXPRESSION AND CELL ADHESIVENESS AND MORPHOLOGY IN THYROID NEOPLASIA, unknown, 2002, 82, ISI Web of Science, 2002, pp120A - 120A Meeting Abstract, 2002

FINN, SP, RET/PTC-3 CORRELATES WITH FOLLICULAR/SOLID MORPHOLOGY IN "SPORADIC" PAPILLARY THYROID CARCINOMA, unknown, 2002, 198, ISI Web of Science, 2002, pp50A - 50A Meeting Abstract, 2002

SMYTH, P, ANALYSIS OF BETA-CATENIN EXPRESSION IN THYROID NEOPLASIA, unknown, 2002, 198, ISI Web of Science, 2002, pp49A - 49A Meeting Abstract, 2002

SMYTH, P, E-CADHERIN EXPRESSION IS REDUCED IN REVPTC-1 BUT NOT REVPTC-3 ACTIVATED THYROID NEOPLASMS, unknown, 2002, 198, ISI Web of Science, 2002, pp11A - 11A Meeting Abstract, 2002

SHEILS, O, SMYTH, P, FINN, S, SWEENEY, EC, OLEARY, JJ, RET/PTC REARRANGEMENTS IN HASHIMOTO'S THYROIDITIS, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 10, 2002, 167 - 168 Miscellaneous, 2002

Finn S, Toner M, Timon C, The node-negative neck: accuracy of clinical intraoperative lymph node assessment for metastatic disease in head and neck cancer., The Laryngoscope, 112, (4), 2002, p630-3 Journal Article, 2002 DOI

SHEILS, OM, IN-VITRO AND IN-VIVO EVIDENCE OF AN ASSOCIATION BETWEEN RET/PTC EXPRESSION AND CELL ADHESIVENESS AND MORPHOLOGY IN THYROID NEOPLASIA, unknown, 2002, 15, ISI Web of Science, 2002, pp120A - 120A Meeting Abstract, 2002

FINN, S, TONER, M, TIMON, C, THE NODE-NEGATIVE NECK: ACCURACY OF CLINICAL INTRAOPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER, LARYNGOSCOPE, 112, 2002, p630 - 633 Journal Article, 2002

FINN, SP, THE NO NECK: ACCURACY OF CLINICAL INTRA-OPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER, unknown, 2001, 14, ISI Web of Science, 2001, pp150A - 150A Meeting Abstract, 2001

FINN, S, SEVERE SYSTEMIC ILLNESS IN HEROIN USERS FOLLOWING INJECTION SITE INFLAMMATION: AUTOPSY FINDINGS IN AN OUTBREAK, unknown, 2001, 81, ISI Web of Science, 2001, pp6A - 6A Meeting Abstract, 2001

Smyth P, Sheils O, Finn S, Martin C, O'Leary J, Sweeney EC, Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms., International journal of surgical pathology, 9, (4), 2001, p265-72 Journal Article, 2001

FINN, SP, THE N0 NECK: ACCURACY OF CLINICAL INTRA-OPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER., unknown, 2001, 81, ISI Web of Science, 2001, pp150A - 150A Meeting Abstract, 2001

FINN, S, SEVERE SYSTEMIC ILLNESS IN HEROIN USERS FOLLOWING INJECTION SITE INFLAMMATION: AUTOPSY FINDINGS IN AN OUTBREAK, unknown, 2001, 14, ISI Web of Science, 2001, pp6A - 6A Meeting Abstract, 2001

SMYTH, P, E-CADHERIN EXPRESSION IN RET/PTC-1 ACTIVATED THYROID NEOPLASMS, DETECTED BY TAQMAN RT-PCR., unknown, 2001, 195, ISI Web of Science, 2001, pp37A - 37A Meeting Abstract, 2001

Finn S, Ryan P, Sleeman D, The medical management of masseteric hypertrophy with botulinum toxin., Journal of the Irish Dental Association, 46, (3), 2000, p84-6 Journal Article, 2000

Research Expertise

Projects

  • Title
    • Identifying non-coding RNA repertoires of aggressive Prostate cancer
  • Summary
    • Abstract: Although there has been significant progress in the basic understanding of why prostate cancer (PCa) arises and how it progresses, these advances, unfortunately, have not translated into a cure and have most often have been disappointing with little benefit to men with aggressive PCa. Clinically relevant biomarkers are lacking and simple prognostication in PCa remains elusive outside of the now decades old pathological Gleason scoring system. Our hypothesis, supported by miRNA data from our laboratories, is that non-coding RNA signatures (including known and novel miRNAs) play a key role in aggressive PCa. In addition, cancer stemness is associated with poor prognosis and aggressive PCa. Therefore, we further hypothesize that non-coding RNA expression profiles, particularly miRNA, are linked to stemness in cancer and a clinically aggressive phenotype. In this application, we aim to model stem cell rich PCa and profile biologically aggressive PCa (high Gleason grade) to identify, in hypothesis neutral experiments, non-coding RNAs associated with aggressive and progressive prostate cancer. miRNAs and their isoMirs will be defined in our holoclone stem cell models and high Gleason score tumours, from the biorepository of the Prostate Cancer Research Consortium (PCRC) in Ireland, and compared to founder cells and indolent prostate cancer respectively. Using advanced bioinformatics we will look for stemness and aggression signatures and use these in a smaller focused panel to assess in relation to outcome in richly and meticulously annotated prostate cancer databases from the Physicians Health Study and Health Professionals Follow Up Study. This study will also uniquely identify ncRNA other than miRNA (piRNA, snoRNA, transcribed ultra-conserved regions) and we expect that these will also contribute to the signatures derived. This study will for the first time provide an in depth profile of isoMirs in prostate cancer. We will also integrate existing and newly undertaken gene expression profiles to examine ncRNA in relation to gene expression patterns and pathways with the aim of deriving integrated ncRNA and mRNA profiles in clinically aggressive PCa. Validation will be performed in independent cohorts and in databases of our collaborators in the United States (Harvard School of Public Health). The latter resource allows us to assess outcome in relation to Prostate cancer specific death rather than PSA failure and is annotated for protein pathway, gene expression profiling and clinical data. Aggressive disease in the Harvard datasets is characterized by the presence of metastases or death from PCa. Finally, in a proof of concept study, we will examine the utility of the profiles discovered to monitor disease progression in circulating tumour cells from patients with aggressive metastatic prostate cancer. With the emergence of ncRNA-based therapeutics there is clear translational potential. The ultimate aim is to translate to the clinic non-coding RNA profiles that can be used to inform treatment options for patients with aggressive prostate cancer.
  • Funding Agency
    • Prostate Cancer Foundation
  • Date From
    • 01/01/12
  • Date To
    • 30/12/14
  • Title
    • EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
  • Summary
    • 1. Abstract 1.1 Background Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer. Their quantitation provides prognostic information. "Cloaking" of CTCs by adherent platelets impedes NK-cell clearance of CTCs from the circulation, enhancing metastatic spread. NK-cell function in blood and in solid organs is quantitatively and qualitatively reduced in obesity. Platelet cloaking may be enhanced in obesity due to the pro-inflammatory, pro-thrombotic state, and may be a mechanism for worse cancer-specific outcomes in this group. Obesity and its biochemical effects may be influenced by lifestyle changes such as exercise. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory effects of obesity. 1.2 Objectives To determine whether 1. Platelet cloaking of PrCa CTCs is more prominent in men with obesity than without 2. Regular exercise can improve quality of life (QoL) and ameliorate platelet cloaking 3. The degree of platelet cloaking varies with levels of systemic and primary tumour inflammation and coagulability 4. Expression of an obesity-associated lethality gene signature leads to variation in platelet cloaking 1.3 Setting and Methods This international multicentre prospective study will recruit 200 men with metastatic PrCa, dividing them into exposed and non-exposed groups based on BMI ≥ 25. Participants will be recruited from centres in Dublin (Ireland), Örebro (Sweden) and London (UK), and will be randomized to intervention and comparison groups. Blood samples will be taken at recruitment (T0) and at three (T3) and six months (T6). Project 1: CTCs will be enumerated in the T0 samples. Adherent platelets will be quantified and compared between the exposed and non-exposed groups, and correlated with clinicopathological parameters. Project 2: The intervention group will undertake a regular supervised aerobic exercise programme, whereas the comparison group will not. T3 and T6 blood samples will be assessed for CTC numbers and platelet cloaking. Changes will be compared with the T0 sample and between exposed and non-exposed and intervention and comparison groups. Participants will complete a detailed questionnaire to assess quality of life and other parameters at each visit. Project 3: All blood samples will be assessed for NK-cell number and activation, markers of systemic inflammation, adipokines and serum factors related to platelet activation. The prostate needle core biopsies will be examined microscopically for atrophy and inflammation, by morphology and immunohistochemistry, with particular reference to NK-cells. All variables will be correlated with platelet cloaking. Project 4: NCBs will be assessed for expression of an obesity-associated lethality gene signature (whose genes are known to play a role in obesity or platelet aggregation and coagulation), and correlated with platelet cloaking. 1.4 Impact This study aims to elucidate a potential mechanism by which obesity confers a worse prognosis in PrCa, two increasingly prevalent diseases in the western world. We hope to show that a low-cost, accessible intervention can improve QoL and potentially ameliorate the effects of obesity through alterations in the systemic adipokine and inflammatory mediator profile.
  • Funding Agency
    • World Cancer Research Fund
  • Date From
    • 01/01/2014
  • Title
    • Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy
  • Summary
    • Scientific Abstract: Building on funding secured from Bayer and Astellas to perform a clinical trial (Phase II Study of Radium-223 in Combination with Enzalutamide in progressive Osseous-Predominant Metastatic CRPC) this translational project will discover new mutations in the Androgen Receptor and validate existing candidates in the Androgen Receptor Ligand binding domain (W741C and F876L) for response to Enzalutamide (ENZ) using serial, liquid biopsies, tissue biopsies and rapid autopsy tissues. Critically we will develop these assays for accurate stratification of patients and for use in routine blood samples collected from patients before and during Enzalutamide therapy using cell free circulating DNA and circulating tumour cells allied to massively parallel next generation sequencing.
  • Funding Agency
    • Irish Cancer Society
  • Date From
    • 01/01/2014

Keywords

ARCHIVAL MATERIAL; BETA-CATENIN; Cancer Molecular Diagnostics; Cancer/Carcinogenesis; CATENIN COMPLEX; Diagnostic bioimaging; DIAGNOSTIC LABORATORIES; DIGESTIVE TRACTS; DISSECTION; E-CADHERIN; EPITHELIAL-CELLS; FROZEN SECTION; GASTRIC CARCINOMAS; GENE; H4 D10S170; HASHIMOTO THYROIDITIS; HEAD AND NECK CANCER; Imaging Techniques; Lipid metabolism; Lung Cancer; NECK DISSECTION; Obesity; ORAL CAVITY; PAPILLARY THYROID CARCINOMA; Pathology; PATTERNS; Prostate cancer; RATIONALE; RET PROTOONCOGENE; RET/PTC-1; SQUAMOUS-CELL-CARCINOMA; STAGING; STAGING PROCEDURE; TAQMAN RT-PCR; TYROSINE PHOSPHORYLATION

Recognition

Representations

Chairman Molecular Pathology, Faculty of Pathology, RCPI 01/02/2011

Memberships

Fellow of the Royal College of Pathologists 2005 – Current


Last updated 21 September 2016 Paul Smyth (Email).